AGIO Agios Pharmaceuticals Inc

2,471

$23.14

$0.59

(2.62%)

Today

Market Cap	$1.29B
Volume (M)	388,553.00
52-Wk High	$31.87
52-Wk Low	$19.80

ST Data

Watchers

New Watcher Rank

Fundamentals

Commit To Purchase Agios Pharmaceuticals At $15, Earn 3.7% Using OptionsStock Options Channel • 3 days ago

Investors considering a purchase of Agios Pharmaceuticals Inc (AGIO) shares, but tentative about paying the going market price of 22.83/share, might benefit from considering selling puts among...

Share to Feed

Agios Pharmaceuticals (AGIO, $22.2) entered Downtrend as Momentum indicator drops below 0 level on Nov 29, 2023Tickeron - Stocks • 8 days ago

This indicator may be signaling that AGIO's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic SyndromesGlobe Newswire • 18 days ago

40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence;One Study Patient Achieved Hemoglobin Response Endpoint Safety Profile Consistent with Data Reported in Healthy...

Agios Pharmaceuticals (AGIO, $22.26) entered Downtrend as Momentum indicator drops below 0 level on Nov 17, 2023Tickeron - Stocks • 20 days ago

Agios Pharmaceuticals GAAP EPS of -$1.64 beats by $0.06, revenue of $7.4M misses by $0.13MSeekingAlpha.com: All News • about 1 month ago

Agios Pharmaceuticals GAAP EPS of -$1.64 beats by $0.06, revenue of $7.4M misses by $0.13M...

Agios Pharmaceuticals reports Q3 EPS ($1.64), consensus ($1.70)The Fly • about 1 month ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Even after rising 5.6% this past week, Agios Pharmaceuticals (NASDAQ:AGIO) shareholders are still down 71% over the past five yearsSimply Wall St • about 1 month ago

We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...

Agios Reports Business Highlights and Third Quarter 2023 Financial ResultsGlobe Newswire • about 1 month ago

First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease Completed Enrollment in Phase 3 ACTIVATE-KidsT Pediatric Study of Mitapivat in PK...

Agios Pharmaceuticals (AGIO, $21.3) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 1, 2023Tickeron - Stocks • about 1 month ago

This is a Bullish indicator signaling AGIO's price could rise from here. Traders may explore going long the stock or buying call options...